Please use this identifier to cite or link to this item:
|Title:||The clinical effectiveness and cost-effectiveness of methylphenidate for hyperactivity in childhood|
|Publisher:||National Institute for Clinical Excellence|
|Citation:||London: National Institute for Clinical Excellence, Version 2, (August 2000).|
|Abstract:||Hyperkinetic Disorder (HD) is characterised by the presence of severe and pervasive signs of inattention, hyperactivity and impulsiveness. It is estimated that approximately 1% of children may meet the diagnostic criteria for HD. The broader definition of Attention Deficit/ Hyperactivity Disorder (ADHD) leads to higher estimates of prevalence. Methylphenidate is a central nervous system stimulant that is indicated for use as part of a comprehensive treatment programme for attention deficit hyperactivity disorder (ADHD) when remedial measures alone prove insufficient. The aim of this review is to evaluate the clinical effectiveness and cost effectiveness of methylphenidate for hyperactivity in childhood.|
|Appears in Collections:||Health Economics Research Group (HERG)|
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.